Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erin Rowan

Nurse Practitioner, Family Tulsa, OK Nurse Practitioner

NPI 1396118972 CMS profile 11232915

6600 S Yale Ave Ste 600, Tulsa, OK 74136

Open in the dashboard

General payments

$12,604

825 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin Rowan of Tulsa, OK is reported in the CMS Open Payments database as having received $12,604 across 825 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,497 74
2024 General $2,007 107
2023 General $1,803 93
2022 General $3,173 222
2021 General $4,124 329

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin Rowan
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Erin Rowan were reported at $1,497. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Erin Rowan Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $4,124 $124 $35–$379 $132
2022 $3,173 $141 $44–$430 $149
2023 $1,803 $154 $49–$476 $160
2024 $2,007 $165 $51–$504 $164
2025 $1,497 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,806 85 payments
  2. Novo Nordisk Inc $1,388 99 payments
  3. Lilly USA, LLC $1,046 79 payments
  4. AbbVie, Inc. $801 71 payments
  5. GlaxoSmithKline, LLC. $665 60 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $581 35 payments
  7. Pfizer Inc. $518 38 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $488 33 payments
  9. Amgen Inc. $487 37 payments
  10. Abbott Laboratories $486 31 payments
  11. Other $4,338 257 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,604 825 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $1,331 62 payments
  2. TRELEGY ELLIPTA $624 52 payments
  3. Kerendia $581 35 payments
  4. Ozempic $542 36 payments
  5. RYBELSUS $528 35 payments
  6. AIRSUPRA $491 14 payments
  7. UBRELVY $442 35 payments
  8. XIFAXAN $435 31 payments
  9. JARDIANCE $427 30 payments
  10. TRULANCE $400 29 payments
  11. Other $9,480 648 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

825 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record